Quadrivalent meningococcal conjugated vaccine: A routine or selective vaccine in Europe?

Cristina Masuet-Aumatell, Raymond Borrow, Jane N. Zuckerman*

*Corresponding author for this work

Research output: Contribution to journalEditorial

3 Citations (Scopus)
Original languageEnglish
Pages (from-to)193-196
Number of pages4
JournalJournal of Infection
Issue number3
Publication statusPublished - Sep 2012

Bibliographical note

Funding Information:
Dr. Masuet-Aumatell received funding for research through the IDIBELL Foundation , the Bellvitge Hospital ; Professor Borrow performs serological evaluation of meningococcal vaccines on behalf of the Health Protection Agency for Pfizer, Novartis Vaccines, Sanofi Pasteur, Sanofi Pasteur MSD, Merck, GSK and Baxter Bioscience; and Dr. Zuckerman has been reimbursed by several manufacturers of vaccines and anti-malarial prophylaxis and received unrestricted educational grants from GlaxoSmithKline, Novartis, Sanofi Pasteur, SBL Vaccines, and Pfizer, for attending conferences, running educational programmes, and undertaking clinical trials. No other potential conflicts of interest have been reported.

Cite this